NCT00871312终止不适用
A Randomized, Double-blinded, Parallel Group, Placebo-Controlled, Multi-Center Trial of Topical Wound Oxygen Therapy in the Treatment of Diabetic Lower Extremity Ulcers
AOTI Ltd.6 个研究点 分布在 2 个国家目标入组 21 人开始时间: 2007年5月1日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 终止
- 发起方
- 入组人数
- 21
- 试验地点
- 6
- 主要终点
- Wound closure
研究概览
简要总结
The purpose of this study is to evaluate the efficacy of the Topical Wound Oxygen (two2) therapy system on the healing of diabetic lower extremity ulcers.
详细描述
The AOTI two2 therapy trial is a randomized, double-blinded, parallel group, placebo-controlled, multi-center study intended to evaluate the efficacy of Topical Wound Oxygen (two2) therapy in relation to placebo when added to standard of care in the treatment of diabetic lower extremity ulcers.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Subject or legal representative has read, understands, and has signed the Institutional Review Board (IRB)-approved Informed COnsent Form (ICF) prior to enrollment in the study;
- •Subject is 18 years of age or older;
- •Subject has a current diagnosis of Type I or Type II diabetes mellitus;
- •Subject has a diabetic lower extremity ulcer;
- •Subject's index ulcer is at least 1.0cm2 in area;
- •Subject's index ulcer is a superficial, partial or full thickness skin ulcer (Wagner Classification System I, II or III) which has been present for at least 4 weeks at the time of initial screening that has not improved with standard of care;
- •Subject's index ulcer appears to be free of sinus tracts and tunneling;
- •Subject's index ulcer exhibits no signs of moderate or severe clinical infection;
- •In the event of multiple wounds on the same foot, the index ulcer will be the largest ulcer meeting the other inclusion criteria;
- •In the event of multiple wounds on the same foor, the index ulcer is at least 2 cm from any additional wound edge;
- •Women of childbearing potential must not be pregnant or lactating;
- •Subject and/or caregiver are willing and able to comply with all specified care and visit requirements, and subject has a reasonable expectation of completing the study;
- •Subject must be fit to undertake the study trial in the opinion of the referring doctor
- •Subject's Great Toe pressure is greater than 20mmHg.
排除标准
- •Subject is currently enrolled in another investigational device or drug trial, or has been previously enrolled in investigative research for a device or pharmaceutical agent within the last 30 days;
- •Subject's index ulcer has gangrene or gangrene is located on any part of the foot with the index ulcer;
- •Subject has an acute and/or active Deep Vein Thrombosis;
- •Subject is currently receiving or has received in the last six (6) months radiation or chemotherapy;
- •Subject has received growth factor therapy within seven (7) days prior to initial screening;
- •Subject has a significant medical condition that would impair wound healing, for example: severe liver disease, aplastic anemia, scleroderma, malnutrition, malignancy, etc;
- •Subject has known or suspected osteomyelitis;
- •Other than debridement, the underlying wound pathology requires surgical correction for the index ulcer to heal;
- •Subject is receiving or has received corticosteroids (all applications), immunosuppressive agents, or other drugs that would impair wound healing within seven (7) days prior to initial screening or is anticipated to require them during the course of the study;
- •Subject has an acute or active Charcot foot per clinical and radiology results or significant bony prominences that would preclude adequate off-loading with the standard off-loading device. The presence of Charcot foot in itself does not exclude the subject;
- •Subject has known HIV, hepatitis, active cancer (except basal cell and non-melanoma skin cancer), or a bleeding disorder;
- •Subject is undergoing renal dialysis;
- •Subject suffers from known alcohol or drug abuse;
- •Use of the standard off-loading device is contra-indicated or cannot be appropriately fitted to the subject.
结局指标
主要结局
Wound closure
时间窗: 12 Weeks
次要结局
- The time to wound closure(Variable)
- The type and amount of wound drainage or exudates(4, 8 and 12 weeks)
- The level of wound pain(4, 8 and 12 weeks)
- The degree of wound closure(4, 8, and 12 weeks)
- The percentage of tissue types(4, 8 and 12 weeks)
研究者
研究点 (6)
Loading locations...
相似试验
撤回
不适用
Pilot Study Comparing NatroxTM Topical Oxygen Therapy to A Placebo in the Management of Non-Healing Leg UlcersSkin Ulcer Venous Stasis ChronicMixed Arteriovenous Leg UlcerNCT01913704Inotec AMD Limited
已完成
不适用
An Observational Clinical Trial Examining the Effect of Topical Oxygen Therapy (NATROX™) on the Rates of Healing of Chronic Diabetic Foot UlcersNon-healing WoundDiabetic Foot UlcerNCT03863054Singapore General Hospital20
已完成
不适用
A Study to Evaluate the Efficacy of OxyjunTM on Cardiac Pumping Capacity as Well as Work Productivity in Individuals With Metabolic Risk.Metabolic DisorderNCT06496880Vedic Lifesciences Pvt. Ltd.64
已完成
3 期
The Role of Oxygen in the Management of Dyspnoea in Advanced CancerCancerNCT00206609Bayside Health50
已完成
2 期
A clinical trial to study the wound healing rates in topical oxygen wound therapy with conventional dressing vs conventional dressings alone in diabetic lower limb ulcers.CTRI/2024/06/068317KLEs Dr Prbhakar Kore hospital and medical research centre.60